Kadimastem, an Israeli biopharma venture, recently declared it was hoping to discuss with the U.S. Food and Drug Administration (FDA) its AstroRX cells experimental therapy,…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.